新生血管性AMD中血管纤维化转换的识别与定量
这项前瞻性观察研究纳入50只治疗初治的新生血管性AMD眼,使用偏振敏感OCT(PS-OCT)定量视网膜下高反射物质(SHRM)体积并检测视网膜下纤维化。28眼基线有SHRM,其中7眼在3个月内出现视网膜下纤维化,6眼可被PS-OCT明确检测。出现纤维化的眼在3个月时SHRM厚度和体积更大,且治疗引起的SHRM减少更不明显。
要点
- PS-OCT可基于双折射检测纤维化、基于去偏振检测RPE。
- 基线有SHRM的28眼中7眼在3个月内出现视网膜下纤维化。
- 纤维化眼在3个月时SHRM厚度和体积更大且治疗反应更差。
核心结论
- 抗VEGF治疗下SHRM体积显著减小,但治疗无反应的病灶最早3个月可进展为纤维化。
- SHRM厚度减少程度可能是治疗反应的预后标志物。
研究设计与样本
- 前瞻性观察研究纳入50例治疗初治新生血管性AMD患者的50只眼。
- CNV类型:1型26眼、2型7眼、混合型11眼、RAP 3眼、PCV 3眼。
- 基线和负荷期结束(3次玻璃体腔抗VEGF注射后)使用PS-OCT成像,扫描角度30°×30°,扫描模式1024×250 A扫描。
- SHRM体积通过逐B扫描手动勾画并在B扫描间插值量化。
- PS-OCT检测的纤维化与视网膜下纤维化的临床表现进行比较。
主要发现
- 50眼中28眼基线存在SHRM。
- 28眼中7眼在3个月内出现视网膜下纤维化,其中6眼可被PS-OCT明确检测。
- 出现纤维化的眼在3个月时SHRM厚度(P=0.001)和体积(P=0.02)显著更大。
- 出现纤维化的眼治疗引起的SHRM厚度减少(P=0.002)和体积减少(P=0.027)显著更不明显。
临床怎么用
- 可利用PS-OCT在抗VEGF治疗早期识别SHRM向纤维化的转换。
- 对SHRM厚度减少不明显的眼应警惕早期纤维化进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We quantify volumetric changes of subretinal hyperreflective material (SHRM) and determine the conversion toward subretinal fibrosis, the angiofibrotic switch, under anti-VEGF therapy using polarization-sensitive optical coherence tomography (PS-OCT). METHODS: A total of 50 eyes of 50 patients with treatment-naïve neovascular age-related macular degeneration (AMD) were included in this prospective observational study: 26 diagnosed with type 1 choroidal neovascularization (CNV), seven with type 2 CNV, 11 with mixed type CNV, three with a retinal angiomatous proliferation (RAP) lesion and three with a polypoidal choroidal vasculopathy (PCV). Patients were imaged at baseline and at the end of the loading phase (after treatment with three intravitreal anti-VEGF injections) using a PS-OCT system with a scanning angle of 30° × 30° and a scan pattern of 1024 × 250 A-scans. The device is capable of detecting fibrosis based on birefringence and the RPE based on depolarization. The volume of SHRM was quantified by manual delineation in each PS-OCT B-scan and interpolation between B-scans using proprietary reading center certified software. The occurrence of fibrosis detected by PS-OCT was compared to the clinical presentation of subretinal fibrosis. RESULTS: Of 50 eyes, 28 had SHRM at baseline. Seven of these eyes had subretinal fibrosis within 3 months, six of which could be detected unambiguously based on PS-OCT imaging. SHRM thickness and volume at month 3 (P = 0.001 and P = 0.02) were significantly larger and the reduction of SHRM thickness and volume (P = 0.002 and P = 0.027) in response to therapy were significantly less pronounced in eyes with fibrosis. CONCLUSIONS: SHRM volume decreases significantly under anti-VEGF therapy. However, lesions unresponsive to therapy may progress to fibrosis as early as 3 months. Reduction in SHRM thickness may be a prognostic marker for treatment response.
引用
- Roberts PK, Zotter S, Montuoro A, et al. Identification and Quantification of the Angiofibrotic Switch in Neovascular AMD. Invest Ophthalmol Vis Sci. 2019. PMID: 30657855. doi:10.1167/iovs.18-25189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。